Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

387.70DKK
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
kr.387.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
324,024
52-wk High
kr.477.70
52-wk Low
kr.280.80

Chart for

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.84
Market Cap(Mil.): kr.76,330.01
Shares Outstanding(Mil.): 198.93
Dividend: 2.45
Yield (%): 0.64

Financials

  LUN.CO Industry Sector
P/E (TTM): 38.10 30.89 32.75
EPS (TTM): 10.07 -- --
ROI: 15.52 15.08 14.60
ROE: 20.33 16.60 16.33

European stocks falter as pharma sector falls

LONDON European shares dipped on Wednesday as poor corporate earnings in the pharmaceutical sector weighed on sentiment already soured by trade tensions, with Washington preparing tariffs on another $16 billion of Chinese goods.

Aug 08 2018

UPDATE 2-European stocks falter as pharma sector falls

* Sentiment still soured by tariff concerns (Adds detail and quote, updates prices at close)

Aug 08 2018

European shares dip as pharmaceuticals' earnings weigh

LONDON European shares dipped on Wednesday as poor corporate earnings in the pharmaceutical sector weighed on sentiment soured by trade tensions, with Washington preparing tariffs on another $16 billion of Chinese goods.

Aug 08 2018

UPDATE 1-Lundbeck drops as its adjusted profit outlook fails to impress

COPENHAGEN, Aug 8 Shares in Lundbeck dropped as much as 10 percent on Wednesday after the Danish drugmaker failed to impress the market with revisions to its full-year profit outlook.

Aug 08 2018

Lundbeck Q2 beats forecast, lifts 2018 guidance

COPENHAGEN, Aug 8 Danish drugmaker Lundbeck on Wednesday posted better than expected second quarter earnings and adjusted its full-year forecast to the upper end of the earlier guidance range.

Aug 08 2018

Lundbeck looks to boost drug range with new CEO

COPENHAGEN, July 2 Danish pharmaceutical company Lundbeck has picked Deborah Dunsire as its new chief executive after former CEO Kaare Schultz was poached by Teva last year.

Jul 02 2018

UPDATE 1-Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

Jun 06 2018

Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it had reached a deal to pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

Jun 06 2018

BRIEF-H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed

* REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)

May 02 2018

Earnings vs. Estimates